Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles
|ClinicalTrials.gov Identifier: NCT00734786|
Recruitment Status : Withdrawn (Study cancelled.)
First Posted : August 14, 2008
Last Update Posted : August 25, 2008
The main objective of the trial is to determine whether the current topical formulation of GTX 2/3 reduces the wrinkling of the skin (crow's feet) after a single application
Other evaluation criteria include: safety assessment and local tolerance, depth of facial wrinkles (video microscopy imaging).
|Condition or disease||Intervention/treatment||Phase|
|Facial Wrinkles||Other: Wrinkle cream application||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles. Study # CLN 08-003.|
|Study Start Date :||August 2008|
|Estimated Primary Completion Date :||September 2008|
|Estimated Study Completion Date :||September 2008|
Placebo Comparator: 2
Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
Other: Wrinkle cream application
Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
Other Name: No other product will be used.
- Depth of facial wrinkles [ Time Frame: 24 hours ]
- Local and general tolerance [ Time Frame: 1day ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00734786
|Buenos Aires, CF, Argentina|
|Principal Investigator:||Silvia H Pérez-Damonte, PhD||CLAIM|